New challenges facing systemic therapies of advancedhcc in the era of different first-line immunotherapy-based combinations

HIGHLIGHTS

• who: Julien Edeline et al. from the Department of, University Rennes, CLCC Eugu00e8ne Marquis, COSS (Chemistry Oncogenesis Stress Signaling)-UMR_S, Rennes, France have published the article: New Challenges Facing Systemic Therapies of AdvancedHCC in the Era of Different First-Line Immunotherapy-Based Combinations, in the Journal: Cancers 2022, 14, 5868. of 24/Nov/2022
• what: The results of tremelimumab used in monotherapy have been published previously, with some evidence of activity in a small phase 2 trial focusing on the Hepatitis-C Virus population (n=21): ORR was 17%, and median OS in second-line . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.